|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.9 USD | -0.78% |
|
-4.33% | -14.47% |
| May. 03 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating | MT |
| May. 02 | Transcript : Ultragenyx Pharmaceutical Inc., Q1 2024 Earnings Call, May 02, 2024 |
Ultragenyx Pharmaceutical Inc. announced the appointment of Amrit Ray, M.D., M.B.A. to the company's Board of Directors. Dr. Ray will serve on the Board's Research and Development Committee. Dr. Ray is Chief Patient Officer for Biohaven Pharmaceuticals, a commercial-stage biopharmaceutical company focused on neurological and neuropsychiatric diseases.
Ultragenyx Pharmaceutical Inc.
| 1st Jan change | Capi. | |
|---|---|---|
| -14.47% | 3.4B | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
ULTRAGENYX PHARMACEUTICAL INC. 